The global burden of hepatitis (inflammation of the liver) infection is still a major public health challenge and burden in the 21 st century, especially in endemic regions due to unavailability of early diagnostic techniques and treatments. The presence of chronic or fulminant hepatitis B virus (HBV) and/ or hepatitis C virus (HCV) infection(s) had caused extensive and irreversible liver damage in different population groups from different parts of the world today, including Nigeria. Aim: The aim of this study was to determine the seropositivity prevalence rates of HBV and HCV infections among pregnant women attending antenatal clinic at the State Specialist Hospital Akure, Ondo State, Nigeria. Materials and Methods: A review of hematological data was done for a period of 1 year which spanned from May 2015 to April 2016. During this period, pregnant women were recruited prospectively from the antenatal clinic and screened for HBV and HCV infections. The evaluation includes risk factor assessment based on age group and determination of rapid serology for hepatitis B surface antigen (HBsAg) and hepatitis C antibodies. Results: The results from our study revealed that out of the 1758 pregnant women recruited and screened, 1.47% and 0.00% within the age range of 25-29 years were positive to HBsAg and HCV, respectively. Conclusion: In conclusion, the 4.2% overall prevalence rate obtained for HBsAg-positive women fell within the reference range for the general population in Nigeria (2.4%-18.4%). The observed overall prevalence value for HBsAg positive women also fell within the 2%-7% reference range for South-Western region geographical prevalence category for Nigeria which showed an intermediate endemic rate within the age range of 25-39 years. The prevalence outcome of this study is an alert threshold attributed to endemic sexual activity of this age range (25-39 years) and prevailing epidemic factors for HBV transmission among reproductive age group.
from an autoimmune disorder in which the body mistakenly sends disease-fighting cells to attack its own healthy tissue in the liver. [1] Transmission of hepatitis B virus (HBV) is by direct contact with the blood or body fluid such as semen, vaginal discharge, breast milk, and saliva of infected persons. [2, 3] HBV and hepatitis C Virus (HCV) have become two of the main viral infection worldwide causing liver disease and hepatocellular carcinoma [4, 5] and as such have become major and possibly growing threats to global health. In terms of the number of people affected and the burden it represents for them, their families, and the healthcare systems of the countries they live in, HBV and HCV are two of the world's most urgent challenges. [5, 6] Viral hepatitis during pregnancy is associated with high risk of maternal complications due to depressed immunity; thus, infection with HBV and HCV during pregnancy is of clinical importance. [1, 7] The symptoms of these diseases may not be easily identified in the early stages. The most common visible symptoms include nausea and vomiting, fatigue, loss of appetite, fever, joint pain, dark urine, muscle and joint pains, abdominal pain jaundice, itching, ascites, bleeding, and bruising. Detection of hepatitis B surface antigen (HbsAg) and HCV antibody in blood is within 30 days and 60 days for new-onset HBV and HCV infections, respectively. Rapid serological tests for antibody detection, enzyme-linked immunosorbent assay method for antigen investigation, and a genomic amplification method for HBV DNA and HCV RNA have been developed to quantify the amount of viruses in the blood. [8, 9] According to a recent World Health Organization (WHO) report, about a third of the total world's population of >2 billion people have serologic evidence of past or present HBV infection, [10] [11] [12] and this includes about 350 million chronic carriers of the virus. Nigeria is classified among the group of countries endemic of HBV infection with a current infected population of 18 million. [13] Annually, up to 1 million of those infected die due to the consequences of infection like liver cirrhosis and hepatocellular carcinoma. [14] It is estimated that >170 million individuals are infected with HCV worldwide, most of them chronically. [15] Hepatitis C was first recognized as a cause of transfusion-associated acute and chronic hepatitis in 1989 and plays a major role as a cause of chronic liver injury with potential for neoplastic degeneration. HCV is responsible for about 350,000 deaths annually, with Southern Europe, particularly Italy among the most affected areas. [16] Prevalence rate differs from place to place. The prevalence of HBV infection according to regional geographical areas may be high (≥8%), intermediate (2%-7%), or low (<2%). [14] Emechebe et al. [17] reported that HBV carriage rate in Nigeria ranges from 9% to 39%, and a carrier rate above 7% in a population is classified as hyperendemic. In moderate prevalence areas, which include Eastern Europe Russia and Japan, about 2%-7% of the population is chronically infected with the disease spreading predominantly among children. [17] The prevalence of HCV in the general population of Africa ranges between 0.1% and 17.5%, depending on the country. The countries with the highest prevalence include Egypt (17.5%), Cameroon (13.8%), and Burundi (11.3%). The countries with the lowest prevalence include Zambia (0.2%), Kenya (0.9%), Malawi (0.7%), and South Africa (0.1%). [18] [19] [20] HCV has a long lag time between onset of infection and clinical manifestation of liver disease (up to 20 years). [21] Viral hepatitis B and C infections are blood-borne and sexually transmitted pathogens that are spread through percutaneous and mucosal exposure to infected blood and body fluids. The route of transmission has important clinical implications because there is a very high probability of developing chronic viral hepatitis if the infection is acquired perinatally (congenitally) or in the preschool years. [22] The use of unsafe injections poses a particular public health problem in developing countries. [23] Research also reveals that contaminated needles cause 8-16 million HBV infections each year, compared with 2.3-4.7 million HCV infections and 80,000-160,000 human immunodeficiency virus infections. [24] Viral hepatitis infection during pregnancy is associated with high risk of maternal complications; in addition, there is a high rate of vertical transmission causing fetal and neonatal hepatitis which can have serious effects which may lead to impaired mental and physical health later in life and a leading cause of maternal mortality, [25] and it is also said to be the most familiar cause of jaundice in pregnancy. [26] Infections by HBV in pregnancy come with its attendant effect on both mother and child. It has been reported that 10%-20% of HbsAg-positive pregnant women transmit the virus to their babies. [27] [28] [29] The aim of this study was to assess the seropositivity prevalence rates, correlate the diseases awareness, and examine the patterns of HBsAg and HCV infection with the associated risk factors among pregnant women attending antenatal clinic at the State Specialist Hospital Akure (SSHA), Ondo State, Nigeria. We also extend the research a step further to determine the age group distribution pattern of HBV and HCV infections among pregnant women receiving antenatal care at the SSHA.
Materials and Methods

Study area
This hospital-based prospective descriptive study was conducted for the duration of one year period from May, 2015 to April, 2016 at the antenatal clinic of SSHA, Ondo State, Nigeria. It receives medical and surgical referrals from within and outside the state.
Study population
One thousand seven hundred and fifty-eight consecutive patients' blood samples were collected from pregnant women attending antenatal clinic at the SSHA, Ondo State. All were screened for HBsAg and HCV antibody by standard methods. The population had a heterogeneous distribution of different age groups, ethnicities, and educational status.
Study design
This study was a hospital-based prospective descriptive study carried out to determine and evaluate the prevalence rates of hepatitis B and C infections among antenatal pregnant women. On antenatal days (every Wednesday), the pregnant women were given health talk on hepatitis infections (HBV and HCV) and HIV/AIDS; they were also advised on the need to know their status. The inclusion criterion for evaluation in this study was all consented pregnant women above the age of 17 years and had formally booked at the antenatal clinic in SSHA. While the exclusion criteria for this study were pregnant women above the age of 17 years who did not grant their informed consents to participate in the study and also pregnant teenagers whose ages were ≤17 years as at the time of antenatal booking or enrollment in this study.
Sample analyses
Sample analyses were carried out at the Haematology/Virology unit of the Haematology Department of SSHA, Ondo State, Nigeria.
Laboratory procedures
Three milliliters of blood were collected from each patient by vein-puncture using sterile syringes and needles into a sterile container with a screw cap. The blood samples collected were centrifuged at 2000 rpm for 5 min to separate the sera. After centrifugation, the sera were labeled and stored in plane vials or tubes at 0°C-20°C for analysis within 24 h.
Hepatitis B surface antigen and hepatitis C virus testing
Serological analysis for HBV and HCV were analyzed using one step HBsAg and HCV antibody test strip manufactured by LabAcon International Diagnostics Limited (LabAcon Biotech, Hangzhou, China). The test kits were evaluated for the presence and qualitative detection of HBsAg and HCV antibodies using a rapid lateral chromatographic immunoassay method. Assays were done at room temperature. The screening was carried out according to the manufacturer's instructions, and interpretation of test results was performed according to the manufacturer's specification. The steps for the laboratory test procedures were carried out based on the recommendations and guidelines from the manufacturer as follows:
Test strip, serum were allowed to equilibrate to room temperature of 25°C-30°C before testing. Test strip was removed from the sealed paunch and used as soon as possible with arrows pointing toward the serum. The test strip was immersed vertically into the serum for at least 10-15 s and placed on a nonabsorbent flat surface with the timer on and then observed for the red or pink line(s) to appear. The results were read after 15 min.
No result was interpreted after 30 min. Two distinct red lines indicate positive, one line in the control region (C) and another line in the test region (T). One red line in the control region (C) and no apparent red line or pink line in the test region (T) indicates negative. Results were invalid when control line fails to appear. Insufficient specimen volume or incorrect procedural techniques were the most likely reasons for control line failure.
Data analysis
Data collected were encoded and analyzed using the Statistical Package for Social Sciences (SPSS) Version 17 (released 2008; SPSS Incorporations, Chicago, Illinois, United States of America). The data generated from this study were presented using descriptive statistics. Results were expressed using frequency and percentage values where necessary. Statistical data analysis for the respective prevalences of HBV and HCV infections was calculated by dividing the number of patients with seropositive samples for each disease condition (as numerator) by the total numbers of patients enrolled in this study, that is, sample size (as denominator).
Ethical clearance and participants' informed consent
Ethical clearance for this study was obtained from the Health Research Ethical Committee of SSHA. In addition, a verbal informed consent was obtained from each of the patients whose laboratory test reports were used, while the laboratory test reports for those who did not grant their informed consent were excluded from the study. Consent was sought from patient's relative where the patient had an impaired level of consciousness. Participants' confidentiality were respected and within the hospital. Provisions were equally made for immunoprophylaxis and vaccination against hepatitis B for the newborn babies.
Infections due to HBV and HCV are significant public health problems around the globe. Worldwide, viral hepatitis is the most common cause of hepatic dysfunction in pregnancy. It is important to screen for HBV and HCV infections in pregnant women because they are considered a sentinel population for which data may be extended to the general sexually active heterosexual population. [29] The 4.2% overall prevalence rate of HBV infection among pregnant women attending antenatal clinic at the SSHA, Ondo State falls within the reference range for reports documented in other studies carried out in other parts of Nigeria, Africa, and the rest of the world. The reported prevalence in this study is an alert threshold because it is high enough to warrant the initiation of routine antenatal screening for HBV infection. This is because HBV positive pregnant women represent a major reservoir of the virus in a community and this can be passed on to the children either vertically or even horizontally. [30] In related studies in different parts of Nigeria, higher prevalence rates of 11.6% were reported among pregnant women in Maiduguri, [31] 13.8% in Lagos, [32] and 8.3% in Zaria [33] and lower prevalence rate of 2.19% in Benin City, [34] 3.8% in Abuja, [35] and 2.89% in Port Harcourt. [36] In some African countries, there were high prevalence rates of 17.3% in Burkino Faso. [37] Lower reports of 6.3% were observed in Tanzania; [14] 1.2% HBV prevalence was reported among antenatal clinic pregnant women in South Africa. [38] Furthermore, in comparison to other findings from the rest of the world where 3.2% was observed at Bonab in East Azerbaijan, [39] and 3.4% was observed at Qazvin in Iran. [40] The prevalence of HCV in this study did not reveal statistical significant seropositivity (0.00%) among the pregnant women studied, compared with 0.5% recorded by Buseri et al., among pregnant women in Yenagoa, Bayelsa state and 1.5% of HCV seropositivity in pregnant women attending the University of Abuja Teaching Hospital, Gwagwalada, Nigeria. [28, 41] maintained by ensuring that no unauthorized person has access to the information on the laboratory test reports, no information can be traced to these patients (as coding system was used for the data analysis sheet instead of writing these patients' names on them), and no unauthorized use of information was made. Table  1 showed the frequency distribution pattern (prevalence rates) of HBsAg in relation to the age groups of the pregnant women attending antenatal clinic at the SSHA, Ondo State, South-Western, Nigeria. The age-specific distribution of HBsAg among individuals in the study showed that those in the age group of 25-29 years had a higher prevalence rate of 26 (1.47%) compared to those in age group 30-34 years which had a lower prevalence rate of 23 (1.31%). There was no prevalence rate observed at the age of 45 years and above.
Results
Prevalence of hepatitis B surface antigen in relation to the age groups of the subjects
Prevalence of hepatitis C virus antibodies in relation to the age groups of the individuals
In this study, the frequency distribution pattern (prevalence rates) of HCV antibodies in relation to the age groups of the pregnant women attending antenatal clinic at the SSHA, Ondo State, South-Western, Nigeria showed no prevalence rate (0.00%) for HCV antibodies. Furthermore, there is no occurrence of HBV and HCV coinfections among the participants.
Discussion
In this study, laboratory test results for HBV and HCV screening were made available to the patients before delivery to the Obstetrics and Gynecology Department. All women who were tested positive for HBsAg were counseled on their status, the modes of disease transmission, the need for neonatal immunization, and close contact screening against HBV infection. They were then referred to a clinical virologist/hematologist/ infectious disease specialist for further investigations, evaluations, and managements in conjunction with the obstetrician and gynecologist team in the antenatal clinic Furthermore, in Gabon, the prevalence of HCV 2.1% in Gabon [42] and 1.03% observed by Kumar et al., 2007 in India has no significant correlation to the prevalence of HCV observed in this present study. [42] This may be related to the peculiarities in the modes of transmission of HCV dictated by sociocultural practices and environmental factors.
The prevalence of HBV infection among pregnant women was detected among the 25-39 age group as follows: the highest infection rate was between 25 and 29 years range with 26 infections (1.47%) followed by the 30-34 years range with 23 infections (1.31%) and 35-39 years range with 15 infections (0.85%). Like in the case of HIV, the highest incidence of the acute infection is among the young adults of 20-30 years.
Habiba and Memon from Pakistan also reported that the majority of those that tested positive to HBV were in the age range 25-35 years which was similar to this present study. [43] Other studies also observed a high prevalence rate of HBV in pregnant women >25 years than those <25 years. [44, 45] A possible reason for the slightly higher HBV prevalence in the 25-39 years age group is the fact that between these ages, many women in urban areas of Ondo State are likely to get married and become pregnant. They are therefore likely to present for the first time at antenatal care and can thus be easily picked up by screening. This could be because all the pregnant women fall within the sexually active age bracket of 25-39 years.
The prevalence of HBV infection according to regional geographical area may be high (≥8%), intermediate (2%-7%), or low (<2%). [46] Previous studies on prevalence of HBV done in South-East Nigeria reported 2.2%, [35] Obi reported 2.9% in South-South Nigeria, Agbede et al., reported 5.7% in North-Central Nigeria, [47] Olokoba reported 8.2% in the North-East Nigeria, [48] and Rabiu et al., reported 6.06% in South-West Nigeria. [49] Studies from the Middle East reported 2.4% of HBV in Saudi Arabia [50] which were lower compared to this present study. Cameroon is generally considered an area of hyperendemicity for hepatitis B infection (prevalence >8%). [51] The prevalence of HBV in this study with other South-West Regions of Nigeria shows an intermediate endemicity of HBV infection according to WHO criteria. [52] The differences in prevalence studies across South-West region could be attributed to different sociocultural practices.
Relative to other findings from other part in Nigeria, Africa, and the world, the 4.2% result obtained in this study is higher than the 3.9% rate reported by Ajayi et al. at Ekiti State, [53] 3.8% reported by Bassey et al., in Abuja, [54] and similar to the 4.3% reported by Akani et al. in Port Harcourt. [55] Furthermore, studies from the Middle East reported 4.3% of HBV in Jordan, [54] 3.7% in Ethiopia, [41] and Kuru et al. recorded 4.2% in Turkey. [56] Comparison of our result with other studies from different countries on pregnant women showed a variable result. The difference in demographic characteristics of the study population such as sociocultural environment, tribal practices, traditional operation, sexual practices, medical exposure, and the difference in hepatitis epidemiology in these countries might explain these significant variable results.
The strength and limitation of this study depend on both the inclusion and exclusion criteria for assessment ; the inclusion criterion for evaluation in this study was all consented pregnant women above the age of 17 years and had formally booked at the antenatal clinic in SSHA while the exclusion criteria for this study were pregnant women above the age of 17 years who did not grant their informed consents to participate in the study and also pregnant teenagers whose ages were ≤17 years as at the time of antenatal booking or enrollment in this study. Finally, the results obtained from this research are exclusively applicable to only pregnant antenatal women in clinical practice setting.
Conclusion and Recommendation
Proper and adequate management of maternal viral hepatitis infection(s) during the antenatal phase ensures better outcomes in the newborn; therefore, screening of pregnant women for HBV and HCV infections is highly necessary and recommended to identify those newborn at risk of transmission. This is to enable preventive measures to be instituted considering the maternal HBV and HCV carriage status, as this is the most effective approach to HBV and HCV infections prevention and control. Government and nongovernmental organizations should intensify efforts to enlighten the general population on the public health consequence and burden of the disease. Hepatitis B and C screening should be permanently incorporated into the routine antenatal investigations for pregnant women. Furthermore, proper healthcare policies should be implemented by the government for maternal and newborn vaccination to reduce the magnitude and burden of HBV infection transmission.
